Search Results



Your search for Caroline Helwick matches 822 pages

Showing 1 - 50


breast cancer

Expert Point of View: Leisha A. Emens, MD, PhD

STUDY DISCUSSANT Leisha A. Emens, MD, PhD, of Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University, Baltimore, entitled her remarks, “Target Practice in Triple-Negative Breast Cancer,” referring to the fact that there is currently no validated target in this aggressive...

breast cancer

Potent PARP Inhibitor Moves Ahead in BRCA-Mutated Breast Cancer

TALAZOPARIB, a novel inhibitor of poly (ADP-ribose) polymerase (PARP), showed encouraging efficacy in breast cancer patients with BRCA1/2 mutations in the phase II ABRAZO trial, presented at the 2017 ASCO Annual Meeting by Nicholas C. Turner, MD, of the Royal Marsden Hospital and The Institute of...

multiple myeloma

Expert Point of View: Michael S. Sabel, MD; Marcela Maus, MD, PhD; and Carl June, MD

"We are now seeing the merger of immunotherapy with precision medicine. This is the epitome of personalized medicine,” said ASCO-invited expert Michael S. Sabel, MD, Chief of the Division of Surgical Oncology at University of Michigan Health Systems, Ann Arbor. He called the effort to target...

multiple myeloma

CAR T-Cell Therapy in Multiple Myeloma Yields 100% Response Rate

Chinese investigators reported that 100% of patients with relapsed or refractory multiple myeloma responded to autologous chimeric antigen receptor (CAR) T-cell therapy, and 14 of 19 (74%) who were followed for a median of 4 months achieved a stringent complete response and have not recurred.1...

breast cancer

Expert Point of View: Leisha A. Emens, MD, PhD

Leisha A. Emens, MD, PhD, of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University, commented on the promise of anti–programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) agents in triple-negative breast cancer. She noted that “an emerging theme...

breast cancer

Pembrolizumab Moving Forward in Triple-Negative Breast Cancer

In the treatment of triple-negative breast cancer, checkpoint inhibition is making inroads in both early- and late-stage disease, and the line of treatment and expression of the programmed cell death ligand 1 (PD-L1) could be important in determining outcomes, according to studies reported at the...

breast cancer

Expert Point of View: Harold Burstein, MD, Carey Anders, MD, and William Sikov, MD

Several breast cancer experts weighed in on the findings of the APHINITY trial. At an ASCO press briefing, Harold Burstein, MD, Associate Professor of Medicine at Harvard Medical School and breast cancer specialist at Dana-Farber Cancer Institute, Boston, pointed out that investigators estimated a ...

breast cancer

Positive Results for APHINITY, but Value of Benefit of Dual HER2 Blockade Questioned

The results of the long-awaited APHINITY trial are in, and although the phase III study met its primary endpoint, it failed to establish dual HER2 blockade as the optimal adjuvant treatment for early HER2-positive breast cancer. After 3 years of follow-up, the addition of pertuzumab (Perjeta) to...

bladder cancer

Strides Being Made in Advanced Urothelial Cancer

According to Srikala S. Sridhar, MD, MSc, FRCPC, of the Princess Margaret Cancer Centre, Toronto, Canada, “It’s an exciting time in the field of urothelial cancer,” thanks to the emergence of new therapies such as the immune checkpoint inhibitors and other approaches that aim to improve both...

solid tumors

Expert Point of View: Sumanta Kumar Pal, MD and John V. Heymach, MD, PhD

ASCO spokespersons at the press briefing lauded the results with larotrectinib and called for broader testing for tropomyosin receptor kinase fusions.  The data for larotrectinib “bring us into a new era where treatment is truly based on mutation, not location,” said Sumanta Kumar Pal, MD, a...

solid tumors

Novel Tropomyosin Receptor Kinase Inhibitor Yields High Response Rates Across Tumor Types

Larotrectinib, an oral inhibitor of tropomyosin receptor kinase, showed “striking” activity in adult and pediatric patients with the genetic aberrations known as tropomyosin receptor kinase (TRK) fusion, researchers reported at the 2017 ASCO Annual Meeting.1 Of 55 patients treated with...

breast cancer

Expert Point of View: Richard S. Finn, MD and Ingrid A. Mayer, MD

Richard S. Finn, MD, of the David Geffen School of Medicine at UCLA, Los Angeles, commented on MONARCH 2 and the field of cyclin-dependent kinase 4/6 (CDK4/6) inhibition in general in an interview with The ASCO Post. “MONARCH 2 is confirmatory for the role of CDK4/6 inhibition in estrogen...

breast cancer

Abemaciclib Plus Fulvestrant Delays Breast Cancer Progression in MONARCH 2

In the treatment of metastatic estrogen receptor–positive breast cancer, a highly significant 45% reduction in progression was achieved with abemaciclib, combined with fulvestrant (Faslodex), in the global phase III MONARCH 2 trial, reported at the 2017 ASCO Annual Meeting by George W. Sledge, MD,...

colorectal cancer

Expert Point of View: Cathy Eng, MD, FACP and Alfred Neugut, MD, PhD

Cathy Eng, MD, FACP, the Sophie Caroline Steves Distinguished Professor in Cancer Research at The University of Texas MD Anderson Cancer Center, Houston, said the trial demonstrates “the challenge of analyzing six individually conducted studies in a pooled analysis.”  The study’s “potential...

gastrointestinal cancer

Some Patients With Stage III Low-Risk Colon Cancer May Require Less Oxaliplatin Therapy

Patients with stage III colon cancer considered at low risk for recurrence may be treated effectively—and incur less neurotoxicity—with 3 months of an oxaliplatin-based regimen as compared with the standard 6 months, according to the results of the International Duration Evaluation of Adjuvant...

breast cancer

Targeting the Androgen Receptor in Breast Cancer

One of the most active areas of research in breast cancer involves the targeting of the androgen receptor. Trials underway for androgen receptor antagonists and modulators, alone and in various combinations of available agents and novel therapies, are yielding encouraging early results. At the 2017 ...

breast cancer

Expert Point of View: Michael Berry, MD

Michael Berry, MD, a breast surgeon who is Director of the Margaret West Comprehensive Breast Center at The West Cancer Center, Memphis, told the The ASCO Post that these findings “echo what surgeons already know,” which is that lymphedema is a result of multiple insults to the axilla. But one...

breast cancer
symptom management

Lymphedema Risk: It’s Not Just About the Surgery

In a study from the Mayo Clinic, Rochester, Minnesota, the risk of lymphedema in a population-based breast cancer cohort was related to multimodality therapy and not axillary surgery alone, investigators reported at the American Society of Breast Surgeons (ASBrS) Annual Meeting.1 “Most patients...

colorectal cancer

Expert Point of View: Manish Shah, MD and Daniel F. Hayes, MD, FACP, FASCO

Manish Shah, MD, Director of Gastrointestinal Oncology at NewYork-Presbyterian and Weill Cornell Medicine, was impressed with the findings of the two subanalyses of CALGB 89803.  “The study found a 46% reduction in the risk of recurrence with two servings of tree nuts a week, and that’s more than ...

colorectal cancer

Tree Nut Consumption May Improve Outcomes in Stage III Colon Cancer

Tree nut consumption, as well as a generally healthy lifestyle, significantly reduced the risk of cancer recurrence and death in patients with stage III colon cancer treated in the Cancer and Leukemia Group B (CALGB) 89803 trial, researchers reported at the 2017 ASCO Annual Meeting. Two subanalyses ...

issues in oncology

Weight Management and Physical Activity in Cancer Care: From Research to Real World

Is there enough evidence to support the incorporation of weight management and physical activity interventions into an oncology practice? And if so, what is the best way to do it? The answer to the first question was a resounding yes from oncologists, patient advocates, dietitians, public health...

prostate cancer

What Is Appropriate Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer?

As the subtleties of metastatic prostate cancer become increasingly recognized, treatment should evolve accordingly, said Jessica M. Clement, MD, Assistant Professor of Medicine at the University of Connecticut Health System and Neag Cancer Center, Farmington. Of particular interest to Dr. Clement ...

supportive care
breast cancer

Anticipate Sexual Dysfunction in Patients on Aromatase Inhibitors

For patients with breast cancer starting on aromatase inhibitors, sexual dysfunction is commonly reported. Early intervention may lessen its impact—but it’s not an easy fix, says a specialist in this area, Leslie R. Schover, PhD. Dr. Schover is Founder of Will2Love, an online sexual health program ...

breast cancer

Expert Point of View: Julie Margenthaler, MD

“This study of 2,759 patients with ductal carcinoma in situ provides data for women who are considering their surgical options,” said Julie Margenthaler, MD, a breast surgeon at Washington University of Medicine, St. Louis, and Communications Chair of the American Society of Breast Surgeons...

breast cancer

Study Establishes Low Risk for Contralateral Breast Cancer After Diagnosis of Ductal Carcinoma in Situ

An increasing number of women with ductal carcinoma in situ are undergoing contralateral mastectomy, but the 5-year risk of cancer in the opposite breast is only about 3%, a study from Memorial Sloan Kettering Cancer Center recently found.1 Investigators hope these numbers will dissuade women from ...

breast cancer

Expert Point of View: Judy C. Boughey, MD

“Inflammatory breast cancer represents the aggressive end of the spectrum of breast cancer at presentation. It is encouraging It to see the high 5-year breast cancer–specific survival rates reported in this cohort of 114 women,” said Judy C. Boughey, MD, a breast surgeon at the Mayo Clinic,...

breast cancer

Triple‑Modality Therapy Achieves Good Control in Inflammatory Breast Cancer

Contemporary triple-modality therapy achieves excellent locoregional tumor control of inflammatory breast cancer, with only 4 locoregional recurrences out of 114 patients treated at The University of Texas MD Anderson Cancer Center, Houston. The investigators described their approach at the...

skin cancer

Intratumoral Plasmid Interleukin-12 Boosts Response to Pembrolizumab

In patients with stage III/IV melanoma, immunologically “cold” tumors were rendered immunologically active through intratumoral injections of plasmid interleukin-12 (IL-12) combined with pembrolizumab (Keytruda).1 Describing the approach at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium,...

head and neck cancer

Expert Point of View: Denise A. Galloway, PhD

Denise A. Galloway, PhD, Associate Director, Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, whose research focus is human papillomavirus (HPV), told The ASCO Post that these findings provide new data for the field. “I can’t think of a large study of oral HPV infection in...

head and neck cancer

Rates of Oral HPV Infection Plummet After Vaccination

Vaccination against the human papillomavirus (HPV) reduced the risk of acquiring oral HPV infections by 88%, in one of the first large studies to explore vaccination’s impact in the oropharynx. The study will be presented at the 2017 ASCO Annual Meeting, and the findings were released in advance of ...

kidney cancer

Prognostic Model May Prove Useful After Nephrectomy

A prognostic model proved able to accurately predict long-term outcomes for patients with stage I to III renal cell carcinoma, the developers of the instrument reported at the 2017 National Comprehensive Cancer Network Annual Conference.1 The model was derived from molecular tissue analysis and...

hematologic malignancies
breast cancer
lung cancer
kidney cancer
sarcoma
bladder cancer
colorectal cancer
multiple myeloma
genomics/genetics

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology®, covering 8 tumor types. Guidelines are now published for more than 60 tumor types and...

solid tumors

First-in-Human Experience With Abemaciclib

The investigational cyclin D–dependent kinase (CDK) 4/6 inhibitor abemaciclib was recently evaluated in several solid tumor types in a phase I multicenter trial.1 Given primarily as a single agent and with continuous dosing, abemaciclib showed encouraging early signals of clinical activity not only ...

solid tumors

CDK4/6 Inhibitors: Their Role in Breast Cancer

The robust progression-free survival benefits achieved with the use of the CDK4/6 inhibitors palbociclib or ribociclib in the metastatic setting provided the impetus to study these agents in early-stage breast cancer. Adjuvant studies are underway, but they take time to mature. For evaluating...

lung cancer

Stage I Lung Cancer: Treatment Advances Have Changed the Game

Read more in the Journal of Oncology Practice (JOP). Visit ASCOPubs.org/journal/jop Patients with stage I lung cancer are achieving excellent local tumor control, thanks to an evolution in radiotherapy and surgical approaches. Jeffrey A. Bogart, MD, Professor and Chair of the Department of...

leukemia

CAR T-Cell Therapy Shows Benefit in Patients With Treatment-Resistant Chronic Lymphocytic Leukemia

Researchers from Fred Hutchinson Cancer Research Center in Seattle reported early results from a small study of their chimeric antigen receptor (CAR) T-cell product (JCAR014) in chronic lymphocytic leukemia (CLL) at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition....

multiple myeloma

Expert Point of Review: Amrita Krishnan, MD

Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research at the City of Hope in Duarte, California, told The ASCO Post that the most exciting drug in the “New Agents” session she moderated at the 2016 American Society of Hematology (ASH) Annual Meeting...

multiple myeloma

Two Studies Show Potential of Venetoclax as Single Agent and in Combination for Myeloma

Early-phase studies suggest that venetoclax (Venclexta) holds promise as a treatment for myeloma. At the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, investigators reported strong activity in heavily pretreated patients, especially those with the t(11;14)...

gynecologic cancers

Expert Point of View: Jonathan Ledermann, MD

Invited discussant Jonathan Ledermann, MD, of UCL Cancer Institute, University College London, said the ARIEL2 results for rucaparib (Rubraca) add to the evidence base for PARP (poly ADP-ribose polymerase) inhibition in ovarian cancer established by olaparib (Lynparza). It’s been about 2 years...

gynecologic cancers

Rucaparib Leads to Frequent Durable Remissions in BRCA-Mutated Relapsed Ovarian Cancer

Rucaparib (Rubraca) led to frequent durable remissions among patients with relapsed high-grade ovarian cancer with BRCA mutations, regardless of whether the mutations were germline or somatic, according to the results of the ARIEL2 trial presented at the 2017 Society of Gynecologic Oncology Annual...

gynecologic cancers

Expert Point of View: Al Covens, MD

Al Covens, MD, Professor and Chair of Gynecologic Oncology at the University of Toronto, and Head of Gynecologic Oncology at Sunnybrook Health Science Centre, commented on the phase II findings of axalimogene filolisbac: “As almost all cervical cancers are human papillomavirus (HPV)-related, this...

gynecologic cancers

Listeria-Based Immunotherapy Improves Survival in Metastatic Cervical Cancer

Overall survival in recurrent, metastatic cervical cancer was substantially extended with a Listeria-based immunotherapy approach that targets the human papillomavirus (HPV), investigators reported at the Society of Gynecologic Oncology Annual Meeting.1 Of 50 evaluable patients, 19 were alive at...

Expert Point of View: Shridar Ganesan, MD, PhD

Shridar Ganesan, MD, PhD, of the Rutgers Cancer Institute of New Jersey, discussed the study on the gut microbiome. Dr. Ganesan noted that response to immunotherapy depends not only on tumor characteristics, but on the immune ­microenvironment as well, and this can clearly be influenced by host...

skin cancer

Gut Bacteria May Enhance, or Hamper, Response to Anti–PD-1 Agents

The microbiome has become an area of intense interest for many health-related reasons. Add to this list the potential for a positive or a negative effect on responsiveness to immunotherapy. Gut microbiota that were more diverse, and that contained an abundance of a particular bacterial species,...

hematologic malignancies

‘Non-Engineered’ T-Cell Therapy Produces Durable Responses in Hematologic Malignancies

Adoptive T-cell therapy using “non-engineered” T cells has been showing activity in hematologic malignancies, according to a presentation by Ann M. Leen, PhD, at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium.1 Dr. Leen is an immunologist and works at the Center for Cell and Gene Therapy,...

gynecologic cancers

Expert Point of View: Eloise Chapman-Davis, MD

Eloise Chapman-Davis, MD, a gynecologic oncologist at New York-Presbyterian and Weill Cornell Medicine, commented on the SOLO2 trial results for The ASCO Post. “SOLO2 is the third randomized trial to evaluate the use of maintenance therapy in a selected subgroup of ovarian cancer patients with...

gynecologic cancers

Olaparib Maintenance Prolongs Progression-Free Survival in Ovarian Cancer

Maintenance therapy with the tablet formulation of olaparib (Lynparza) significantly prolonged progression-free survival in patients with platinum-sensitive relapsed ovarian cancer and mutations in BRCA1/2 in the phase III SOLO2 trial, presented at the 2017 Society of Gynecologic Oncology (SGO)...

Anne Friedman Glauber, Cofounder of Online Pancreatic Cancer Forum, Dies at Age 63

Anne Friedman Glauber, 63, co-founder of Let’s Win, an online community for persons affected by pancreatic cancer, recently passed away at her home in New York City, after a courageous battle with the disease. Ms. Glauber’s dedication to the organization (www.letswinpc.org) helped countless...

lymphoma

The Art of Medicine in the World of Evidence-Based Medicine

Christian Taverna, MD, a lymphoma specialist at the Hospital Münsterlingen in Switzerland, commented on this patient series for The ASCO Post. He noted that the Swiss Group for Clinical Cancer Research (SAKK) tried to address the question of the optimal duration of rituximab (Rituxan) maintenance...

lymphoma

For One Hematologist, No Disease Progressions in Follicular Lymphoma With Rituximab Maintenance

Patients with follicular lymphoma are clearly living longer without disease progression, but what clinician has had no patients progress? Michael Auerbach, MD, a hematologist/oncologist in private practice in Baltimore and Clinical Professor of Medicine at Georgetown University, may have these...

Advertisement



Advertisement


Advertisement